Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Pilavapadin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lexicon Pharma To Release Ph 2b Results For Diabetic Neuropathic Pain
    Lexicon Pharma To Release Ph 2b Results For Diabetic Neuropathic Pain

    03 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/02/3035198/0/en/Lexicon-Pharmaceuticals-to-Announce-Topline-Results-from-Phase-2b-PROGRESS-Study-Evaluating-Pilavapadin-LX9211-in-Adults-with-Diabetic-Peripheral-Neuropathic-Pain.html

    GLOBENEWSWIRE
    03 Mar 2025
    Share Share
    Lexicon Ph2b Study Shows Pilavapadin Benefit In Diabetic Pain
    Lexicon Ph2b Study Shows Pilavapadin Benefit In Diabetic Pain

    03 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/03/03/3035469/0/en/Lexicon-Pharmaceuticals-Announces-Topline-Results-from-Phase-2b-PROGRESS-Study-Evaluating-Pilavapadin-LX9211-in-Adults-with-Diabetic-Peripheral-Neuropathic-Pain.html

    GLOBENEWSWIRE
    03 Mar 2025
    Share Share